Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc V.VIV.H

Alternate Symbol(s):  VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


TSXV:VIV.H - Post by User

<< Previous
Bullboard Posts
Next >>
Post by DrJayseron Feb 20, 2020 4:01pm
117 Views
Post# 30714577

No News , I guess its not important

No News , I guess its not importantSubject to the terms of this Agreement, Avivagen hereby grants to CSA the exclusive right to market, promote and distribute the Product in the Field of Use in the Territory during the Term (“Exclusivity”). For the avoidance of doubt, CSA must meet the annual performance targets in Schedule A in each category specified in order to maintain the Exclusivity for each category within the Field of Use (the “Performance Targets”). Exclusivity is also subject to compliance with the terms of Section 2.6 (Restrictive Covenants)

2.6 Restrictive Covenants. a. Non-Compete. As long as CSA is the exclusive distributor of the Product in at least one category of the Field of Use in the Territory, CSA shall not enter into a similar arrangement for any new product that is competitive to or a replacement for the Product. Non-Solicitation. During the Term and for twelve (12) months after termination, CSA shall not actively promote or recommend any new competitive products to customers who are currently purchasing the Product. For the avoidance of doubt, the restrictions in this Section 2.6(b) shall not apply if Avivagen terminates this Agreement pursuant to Section 5.2.

DISTRIBUTION AGREEMENT 15 SCHEDULE “A” Performance Targets Annual Performance Targets (calculated as 12-month terms starting on the Effective Date): POULTRY Product Year Quantity in Metric Tons OxC-Beta Livestock ™ Year 1 7 Year 2 20 Year 3 37 Year 4 TBD* Year 5 TBD* * to be agreed prior to the end of Year 3 SWINE Product Year Quantity in Metric Tons OxC-Beta Livestock ™ Year 1 4.5 Year 2 12 Year 3 25 Year 4 TBD* Year 5 TBD*
<< Previous
Bullboard Posts
Next >>